Linezolid pharmacokinetics and pharmacodynamics in clinical treatment.
about
New developments in the management of severe skin and deep skin structure infections - focus on tedizolidCo-therapy using lytic bacteriophage and linezolid: effective treatment in eliminating methicillin resistant Staphylococcus aureus (MRSA) from diabetic foot infectionsPlatelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials.Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients.Fish tank granuloma caused by Mycobacterium marinumVariability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational studyAntibacterial Treatment of Meticillin-Resistant Staphylococcus Aureus Complicated Skin and Soft Tissue Infections: a Cost and Budget Impact Analysis in Greek Hospitals.Validation of a new HPLC-UV method for determination of the antibiotic linezolid in human plasma and in bronchoalveolar lavage.Oral antibiotic therapy for the treatment of infective endocarditis: a systematic reviewA 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening.In Vivo Assessment of Phage and Linezolid Based Implant Coatings for Treatment of Methicillin Resistant S. aureus (MRSA) Mediated Orthopaedic Device Related Infections.Can enteral antibiotics be used to treat pneumonia in the surgical intensive care unit? A clinical outcomes and cost comparison.Xenobiotics that affect oxidative phosphorylation alter differentiation of human adipose-derived stem cells at concentrations that are found in human blood.Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis.In vivo bioluminescence imaging to evaluate systemic and topical antibiotics against community-acquired methicillin-resistant Staphylococcus aureus-infected skin wounds in mice.Dissecting the mechanisms of linezolid resistance in a Drosophila melanogaster infection model of Staphylococcus aureus.Newer antibiotics for the treatment of peritoneal dialysis-related peritonitis.Critical Role of Alpha-Toxin and Protective Effects of Its Neutralization by a Human Antibody in Acute Bacterial Skin and Skin Structure Infections.Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).The emergence of linezolid resistance among Enterococci in intestinal microbiota of treated patients is unrelated to individual pharmacokinetic characteristicsSelection of antibiotics for meticillin-resistant Staphylococcus pseudintermedius: time to revisit some old drugs?Antimicrobial resistance in internal medicine wards.Subtherapeutic linezolid concentrations in a patient with morbid obesity and methicillin-resistant Staphylococcus aureus pneumonia: case report and review of the literature.Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium.Multi-functional scaling methodology for translational pharmacokinetic and pharmacodynamic applications using integrated microphysiological systems (MPS).Effects of continuous renal replacement therapy on linezolid pharmacokinetic/pharmacodynamics: a systematic reviewMitochondrial antibiograms in personalized medicine.Methicillin Resistant Staphylococcus aureus Prostatic Abscess with Bacteremia.Unveiling the Synergistic Interaction Between Liposomal Amphotericin B and Colistin.Pharmacologic concentrations of linezolid modify oxidative phosphorylation function and adipocyte secretome.Linezolid-induced optic neuropathy with a rare pathological change in the inner retina.Repurposing auranofin as an intestinal decolonizing agent for vancomycin-resistant enterococci.Linezolid: a review of its properties, function, and use in critical care.
P2860
Q28083116-361DFEDA-43B6-4293-95E1-0818DD977831Q28394377-C7002EE4-7D1C-4EDC-92FF-D4C1C880F82EQ33417790-658BA802-A8F8-4507-828E-BA92E6BE3AEEQ33439246-04C79BF3-C1E7-46C6-9304-BE2BD99B52DEQ34387801-A3A15547-9F8E-49ED-BA4B-891C8D3B5411Q34486095-57702424-4B6E-4617-AD28-AF4464CC489EQ34726077-199B99E8-5D9A-47FF-93DB-CE128BC8E576Q34787394-28BD5D19-8A02-4A0B-8590-13886EF36620Q35119494-3EAE57AA-BB58-45A2-9D59-6B6A05C4B0FBQ35617587-D8FD7B90-D516-4E23-83AC-5992AC2D5834Q35996715-F94324B0-80E3-4DD7-8D1C-6B1FBBD11AAEQ36059113-DA51996B-B2D8-466D-8B14-A31F1D571757Q36184433-DB1F6C69-E1FA-4C7C-AE5A-318984F234C4Q36245186-B784AF5C-6B5B-4860-A1C7-82332413C402Q36364155-1BD241BA-B970-489A-A102-891AAADD9964Q36558524-662BB150-F094-4F9E-86B3-3870A7145031Q36882517-6E28A0B0-E320-4127-83F5-F00584CF6B66Q37119083-6EE03C6D-4A31-470B-9178-43A3FE800707Q37287845-E5524E19-8307-44C8-8EF1-8A11CE8D7B37Q37377897-C2A5274B-FCE7-4C31-A789-A493D64B61A9Q37712989-0B401C3A-E447-4BF4-A603-5550D2133EEBQ37982099-11FA7B7E-D08E-4B61-81A9-BC929343FE2BQ38052855-593CAD47-B037-46BD-A4E8-D280336D9C53Q38106836-8DF5A4B3-0FBC-4BBC-BCD1-2CCE9D3AC603Q38325502-AD695B1C-CB3B-4DD7-B528-717E94A375E5Q38925148-598F08AF-3B01-49ED-9B9E-D6AB4EF70D2CQ39013332-11AB35C2-EB4E-46AE-B502-D2ECB845D21AQ39230101-6AE1903E-1338-4DD3-AE99-F2FB5BDDDF67Q40220413-88EAED54-2E39-444A-B17A-A27804FFA9A7Q41071187-49E0E5D7-08CB-4624-8C66-BD15AE6CA3CAQ42209647-605805CA-DA4E-4F66-A4FF-1FF6668B2A5CQ51526260-56C52740-793A-40DE-BFA8-C75938F0CCB7Q55016563-1D40AE6D-6A6D-4594-B543-FA5BE5B5386AQ55368160-E3A71767-06B8-4000-A3F0-F91D0433CE9C
P2860
Linezolid pharmacokinetics and pharmacodynamics in clinical treatment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Linezolid pharmacokinetics and pharmacodynamics in clinical treatment.
@en
Linezolid pharmacokinetics and pharmacodynamics in clinical treatment.
@nl
type
label
Linezolid pharmacokinetics and pharmacodynamics in clinical treatment.
@en
Linezolid pharmacokinetics and pharmacodynamics in clinical treatment.
@nl
prefLabel
Linezolid pharmacokinetics and pharmacodynamics in clinical treatment.
@en
Linezolid pharmacokinetics and pharmacodynamics in clinical treatment.
@nl
P2860
P356
P1476
Linezolid pharmacokinetics and pharmacodynamics in clinical treatment.
@en
P2093
Matthew S Dryden
P2860
P304
P356
10.1093/JAC/DKR072
P407
P478
66 Suppl 4
P577
2011-05-01T00:00:00Z